Need to see if the weakness comes back in the near term it almost retested the 52 week high today. Without that very lofty Stifel target raise today I think this would have closed near $550 today.
If we see a sell in May 5-7% correction you may get that price. Momentum works in both ways especially to the down side in a bad market.
He liked it minutes before the open today based on the Stifel target which I think is a bit on the high side. This stock was showing weakness since the $576.13 high and I guess it was time for an upgrade this morning that's how WS works especially if the firm is in the stock.
Stifel came out with their call at 10pm last night. Stifel and Jefferies are out today upgrading a lot of things. To me their target bump seems a bit high I would guess they are long NFLX and have seen it struggling lately since the report and it's time to give it a boost. Let's see the action today and if it can break out or continue the weakness which I would guess may be some profit-taking after a $100 in two days. I would love to see a pull back to the $520-$530 area then I would start to nibble for a move back to the recent high.
I have sympathy for those who got hurt by the new rules. I believe he was actually trying to help those who had no care along with trying to keep the poor out of emergency rooms. The US health care system is very complicated when you are dealing with the providers who have the best lawyers/doctors who can skirt any negative factors in new laws to roll them in their favor. Based on all the health care share prices I would say they may have benefited under Obama possibly more than even under Bush. As for myself I am fortunate to have carried my coverage into retirement with affordable premiums and deductibles for myself and my family of course until my children are 26 which is getting closer.
You may be right I had it on my screen all day and it looks like it wants to go lower especially the way it closed today.
It just goes to show how arbitrary analysts calls are especially with drug an biotech stocks. It seems that they almost never consider that trials and testing can fail or be delayed. This stock is a poster child along with a littered trail of others who did not meet the end goals. I've been buying OHRP from $2.90's to the $2.50's and a few weeks later it seems to be getting a bid.
It's dropping no surprise too far too quick on one report. I would guess you will see some profit-taking next week. The extra gains were a momentum based short squeeze and MSFT added over $37 billion in one day. I think the market will figure it out whether it is justified in one day
Up over 10% that's a large move for a big ship like MSFT this had a $41+ in front of it last week. The Nazdaq is at all-time highs something's got to give soon. If this gets near $48 I will nibble a little on the short side for a trade. This is starting to look like the GE trade a few weeks ago and that pulled back a pretty good amount.
to neutral from buy today. Just curious why this call was not made over $40 now that shares are over $6 off the recent high. These firms get short from higher levels and want to increase their profits is my guess.
Most of the oil plays will survive even the $10-$20 stocks since most have slashed their dividends and cut the cap-x to align their current production to the demand that's out there. Personally I believe the oil trade has moved up to quick based on inventory levels. The sad part is that these same traders based on making money (mostly now by squeezing shorts) have not allowed the American consumer to enjoy those really low prices for too long. If the Fed raises rates in June ( I don't think they will) then the strong dollar play comes back and oil prices may stabilize or even fall some.